Innovations in Drug Target Validation
	SMi , The Hatton, London 7th-8th February 2001
	Innovations in Drug Target Validation Day One – 7th February 2001 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Prof William Shaw, Chief Scientific Officer, PanTherix RECENT DEVELOPMENTS IN TARGET VALIDATION TECHNOLOGY 9.10 Past, present and future of target validation technology in the pharmaceutical industry Dr Deborah Baly, Director, Cell and Analytical Biology, Bayer THE DISCOVERY AND VALIDATION OF NEW DRUG TARGETS TO FIND THE R&D PIPELINE 9.40 The Aventis approach Prof Graham Boulnois, Senior Vice President, Global Lead Innovation, Aventis FROM DRUG TO TARGET 10.20 Identifying targets by identifying mechanisms of action Dr Mark Cockett, Executive Director, Functional Genomics, Bristol Myers Squibb 11.00 Morning coffee A UNIFIED APPROACH TO TARGET VALIDATION 11.20 Case study: Synomics Simon Beaulah, Product Manager, Synomics TISSUE PROFILING TO IDENTIFY TARGETS 12.00 Decreasing your target options by utilising multiple models Dr Andrew Eisen, Project Leader Metabolic Diseases, CuraGen 12.40 Lunch SIMPLE ORGANISMS AS MODELS 1.40 Advantages of using simple organisms as functional genomic models Dr David Matthews, Associate Director, Drug Discovery, Exelixis METABOLIC DISEASE TARGET VALIDATION 2.20 Data mining and effective use of model organisms to identify targets Dr Patricia Kilian, Vice President, Research, Metabolic Diseases, Pharmacia TRANSGENIC APPROACHES 3.00 Commercial viability of transgenic approaches to target validation Dr Kazimierz Babinski, President & CEO, Antalium 3.40 Afternoon tea COMPUTATIONAL APPROACHES TO NOVEL TARGET IDENTIFICATION 4.00 The availability of genomic technology will drive future target and lead discovery efforts David Kulp, Chief Technology Officer, Neomorphic TARGET VALIDATION USING FOLD RECOGNITION 4.30 Fold recognition as a method of assigning function Dr Ben Hitz, Scientific Applications Manager, Proceryon 5.00 Chairman’s Closing Remarks and Close of Day One 5.10 Networking Drinks Reception Innovations in Drug Target Validation Day Two – 8th February 2001 8.30 Re-registration and Coffee 9.00 Chairman's Opening Remarks Dr Juergen Hammer, Research Leader, Head of Genomics Section, Hoffman-La Roche INDENTIFYING TARGETS IN HUMAN TISSUE 9.10 The GPCR database project Dr Julian Beesley, European Sales Director, LifeSpan Biosciences ANTISENSE TECHNOLOGY AND TARGET VALIDATION 9.40 High throughput functional genomics and target validation using antisense technology Dr Frank Bennett, Vice President, Antisense Research, Isis VALIDATION OF DRUG TARGETS IN COMMONE DISEASE USING HUMAN POPULATIONS 10.20 Case study: Gemini Genomics Dr Patrick Kleyn, Chief Scientific Officer, Gemini Genomics 11.00 Morning coffee VALIDATING CANCER TARGETS 11.20 Overview of cancer target validation Dr Bruce Roberts, Vice President, Applied Genomics, Genzyme Molecular Oncology TARGET DISCOVERY AND VALIDATION IN CANCER RESEARCH 12.00 Identifying aberrantly expressed cell cycle molecules as targets for oncology drug development Dr Ying Luo, Senior Director, Genomics and Target Discovery, Rigel 12.40 Lunch VALIDATING ANTIGENIC TARGETS 1.40 Case study: validation of PSCA as a antigenic target Dr Aya Jakobovits, Vice President, Research & CSO, UroGenesys TARGET IDENTIFICATION AND VLIADATION USING A FUNCTIONAL PROTEOMICS APPROACH 2.20 Case study: KineomicsTM Dr Jasbinder Sanghera, Vice President, Drug Discovery, Kinetek PROTEOMICS & TARGET VALIDATION 3.00 How can proteomics be applied to drug target validation? Dr Bassil Dahiyat, President & CEO, Xencor 3.40 Afternoon Tea GENE EXPRESSION ARRAYS 4.00 Target Validation by combining evidence from gene expression arrays Adesh Kaul, Marketing Manager, Genedata EVIDENCE-BASED TARGET VALIDATION 4.30 Case study: an integrated approach to target validation Dr Uli Hacksell, Executive Vice President, Drug Discovery, ACADIA 5.00 Chairman's Closing Remarks and Close of Conference
	Organized by:	SMi
	Invited Speakers:	Prof Graham Boulnois, Senior Vice President, Global Lead Innovation, Aventis Dr Mark Cockett, Executive Director, Functional Genomics, Bristol Myers Squibb Dr Deborah Baly, Director, Cell and Analytical Biology, Bayer Dr Patricia Kilian, Vice President, Research, Metabolic Diseases, Pharmacia Dr Bruce Roberts, Vice President, Applied Genomics, Genzyme Molecular Oncology Dr Aya Jakobovits, Vice President, Research & CSO, UroGenesys Dr Andrew Eisen, Project Leader Metabolic Diseases, CuraGen Dr David Matthews, Associate Director, Drug Discovery, Exelixis Dr Bassil Dahiyat, President & CEO, Xencor Dr Jasbinder Sanghera, Vice President, Drug Discovery, Kinetek Dr Frank Bennett, Vice President, Antisense Research, Isis Dr Ying Luo, Senior Director, Genomics and Target Discovery, Rigel Dr Ben Hitz, Scientific Applications Manager, Proceryon Dr Julian Beesley, European Sales Director, LifeSpan Biosciences Dr Uli Hacksell, Executive Vice President, Drug Discovery, ACADIA Dr Patrick Kleyn, Chief Scientific Officer, Gemini Genomics Simon Beaulah, Product Manager, Synomics David Kulp, Chief Technology Officer, Neomorphic Dr Kazimierz Babinski, President & CEO, Antalium Adesh Kaul, Marketing Manager, Genedata Dr Juergen Hammer, Research Leader, Head of Genomics Section, Hoffman La Roche Prof William Shaw, Chief Scientific Officer, PanTherix
	Deadline for Abstracts:	passed
	Registration:	Tel +44 (0)78276066
	Email for Requests and Registration:	swatt@smiconferences.co.uk
	Posted by: suzanne watt   Host: 213.38.112.46 date: December 12, 2000 17:15:35 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.